Stefan Habringer, Hematologist/Oncologist and Junior Group Leader at Charité, shared a post on LinkedIn about a paper he co-authored with colleagues, published in the Molecular Cancer Therapeutics:
“Happy to share our work on a new epigenetic biomarker in multiple myeloma! Very proud of my former doctoral student, now oncologist in training Dr. Kaiting Jiang, whose work ethic and creativity pushed this project to the next level.
- KANSL2 regulates histone acetylation, is highly expressed in a subset of multiple myeloma patients and associated with adverse prognosis.
- KANSL2 makes myeloma cells resistant to chemotherapy by protecting them from DNA damage.
- The biological program elicited by KANSL2 can be targeted by histone deacetylase (HDAC)- and BET-inhibitors and particularly their combination.
- We developed an AI-guided ex vivo assay that can measure both KANSL2 expression levels and response to HDAC- and BET-inhibitor.
This work provides first translational evidence that biomarker-guided patient selection might be the way to re-purposing panobinostat and BET-inhibitors in myeloma.
A big thank you goes out to all co-authors Marieluise Kirchner, Frederik Herzberg, Yan Zhao, Amelie Gasper, Francis Baumgartner, Paul Jung, Jan Braune, Veronika Schulze, Konstandina Isaakidis, Philipp Mertins, Jan Krönke and Ulrich Keller.
…and of course to Else Kröner-Fresenius-Stiftung for funding this work!
I am also honored that Robert Orlowski and OncoDaily highlighted the paper as ‘Myeloma Paper of the Day‘ on Thanksgiving.”
Title: The histone modifier KANSL2 is an actionable biomarker in multiple myeloma
Authors: Kaiting Jiang, Marieluise Kirchner, Frederik Herzberg, Yan Zhao, Amelie Gasper, Francis Baumgartner, Paul Jung, Jan Braune, Veronika Schulze, Konstandina Isaakidis, Philipp Mertins, Jan Krönke, Matthias Wirth, Ulrich Keller, and Stefan Habringer
You can read the Full Article in Molecular Cancer Therapeutics.
